Literature DB >> 23329227

The association between early atrial arrhythmia and long-term return to sinus rhythm for patients following the Cox maze procedure for atrial fibrillation.

Niv Ad1, Linda Henry, Sari D Holmes, Lori E Stone, Sharon Hunt.   

Abstract

OBJECTIVES: Observational studies identified increased age, left atrial (LA) size, type and duration of atrial fibrillation (AF) as independent predictors for failure of AF surgical ablation. Rhythm at discharge following the Cox maze (CM) procedure for AF was never considered a significant predictor of success. The purposes of this study were to: (i) Determine the association of sinus rhythm (SR) at discharge and maintenance of SR. (ii) Identify the variables associated with discharge rhythm. (iii) Identify the effects of discharge rhythm on health-related quality of life (HRQL) post-CM procedure.
METHODS: A prospective study (n = 534) of CM III/IV patients. Rhythm captured during hospitalization, discharge, 3, 6, 12 and 24 months and verified by electrocardiogram and 24-h holter. Subsequent SR interventions were captured. Logistic regression identified predictors of discharge rhythm. HRQL (Short-Form 12; AF symptom frequency and Severity Checklist V3) obtained during follow-up.
RESULTS: Eighty-eight percent were discharged in SR (n = 469). LA size (OR = 1.36, CI: 1.02-1.82, P = 0.035) and long-standing AF type (OR = 2.68, CI: 1.31-5.50, P = 0.007) were the only independent predictors of non-SR at discharge. Lower rates of SR at 2 years were found in patients discharged in non-SR (75 vs 91%, P = 0.01). Patients discharged in SR had fewer perioperative morbidities [prolonged ventilation >24 h (6 vs 14%, P = 0.03), renal failure requiring dialysis (0.9 vs 5%, 0.04) and pneumonia (2 vs 9%, P = 0.005)]. During follow-up (mean = 43 ± 27 months), patients discharged in SR had fewer cardioversions (15 vs 29%, P = 0.006), similar percutaneous catheter ablations (6 vs 5%, P = 1.00) and no difference in late embolic strokes (1.5 vs 1.1%, P = 0.54).
CONCLUSIONS: In this large prospective cohort study, rhythm at discharge was found to be clinically significant with predicting SR at 24 months. Surgeons should be aware that the prognosis of non-SR patients at discharge remains excellent with high rates of SR at 24 months if managed appropriately using rhythm rather than rate control strategies.

Entities:  

Keywords:  Atrial arrhythmia; Cox maze procedure; Long-term success; Surgical ablation

Mesh:

Year:  2013        PMID: 23329227     DOI: 10.1093/ejcts/ezs708

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Late outcomes after the Cox maze IV procedure for atrial fibrillation.

Authors:  Matthew C Henn; Timothy S Lancaster; Jacob R Miller; Laurie A Sinn; Richard B Schuessler; Marc R Moon; Spencer J Melby; Hersh S Maniar; Ralph J Damiano
Journal:  J Thorac Cardiovasc Surg       Date:  2015-08-08       Impact factor: 5.209

2.  Early Stable Sinus Rhythm Associated With Greater Success 5 Years After Surgical Ablation.

Authors:  Niv Ad; Sari D Holmes
Journal:  Ann Thorac Surg       Date:  2018-01-08       Impact factor: 4.330

3.  Comparison of the stand-alone Cox-Maze IV procedure to the concomitant Cox-Maze IV and mitral valve procedure for atrial fibrillation.

Authors:  Christopher P Lawrance; Matthew C Henn; Jacob R Miller; Laurie A Sinn; Richard B Schuessler; Ralph J Damiano
Journal:  Ann Cardiothorac Surg       Date:  2014-01

4.  Late outcome of surgical radiofrequency ablation for persistent valvular atrial fibrillation in China: a single-center study.

Authors:  Hailong Cao; Yunxing Xue; Qing Zhou; Minggang Yu; Chenbin Tang; Dongjin Wang
Journal:  J Cardiothorac Surg       Date:  2017-08-03       Impact factor: 1.637

5.  The long-term efficacy of concomitant maze IV surgery in patients with atrial fibrillation.

Authors:  Camilla Skals Engelsgaard; Kenneth Bruun Pedersen; Lars Peter Riber; Peter Appel Pallesen; Axel Brandes
Journal:  Int J Cardiol Heart Vasc       Date:  2018-04-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.